| Microbial translocation is a cause of systemic immune activation in chronic HIV infection JM Brenchley, DA Price, TW Schacker, TE Asher, G Silvestri, S Rao, ... Nature medicine 12 (12), 1365-1371, 2006 | 4352 | 2006 |
| Immune-related adverse events with immune checkpoint blockade: a comprehensive review JM Michot, C Bigenwald, S Champiat, M Collins, F Carbonnel, ... European journal of cancer 54, 139-148, 2016 | 2231 | 2016 |
| Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome L Fardet, L Galicier, O Lambotte, C Marzac, C Aumont, D Chahwan, ... Arthritis & rheumatology 66 (9), 2613-2620, 2014 | 1328 | 2014 |
| Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study A Sáez-Cirión, C Bacchus, L Hocqueloux, V Avettand-Fenoel, I Girault, ... PLoS pathogens 9 (3), e1003211, 2013 | 1192 | 2013 |
| Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination C Boutros, A Tarhini, E Routier, O Lambotte, FL Ladurie, F Carbonnel, ... Nature reviews Clinical oncology 13 (8), 473-486, 2016 | 1123 | 2016 |
| Immune-related adverse events of checkpoint inhibitors M Ramos-Casals, JR Brahmer, MK Callahan, A Flores-Chávez, N Keegan, ... Nature reviews Disease primers 6 (1), 38, 2020 | 1100 | 2020 |
| Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper S Champiat, O Lambotte, E Barreau, R Belkhir, A Berdelou, F Carbonnel, ... Annals of Oncology 27 (4), 559-574, 2016 | 1069 | 2016 |
| Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial O Hermine, X Mariette, PL Tharaux, M Resche-Rigon, R Porcher, ... JAMA internal medicine 181 (1), 32-40, 2021 | 929 | 2021 |
| HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype A Sáez-Cirión, C Lacabaratz, O Lambotte, P Versmisse, A Urrutia, ... Proceedings of the National Academy of Sciences 104 (16), 6776-6781, 2007 | 768 | 2007 |
| Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases JE Gottenberg, L Guillevin, O Lambotte, B Combe, Y Allanore, ... Annals of the rheumatic diseases 64 (6), 913-920, 2005 | 520 | 2005 |
| HIV controllers: a homogeneous group of HIV-1—infected patients with spontaneous control of viral replication O Lambotte, F Boufassa, Y Madec, A Nguyen, C Goujard, L Meyer, ... Clinical Infectious Diseases 41 (7), 1053-1056, 2005 | 501 | 2005 |
| Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors E De Martin, JM Michot, B Papouin, S Champiat, C Mateus, O Lambotte, ... Journal of hepatology 68 (6), 1181-1190, 2018 | 480 | 2018 |
| Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French autoimmunity and rituximab registry B Terrier, Z Amoura, P Ravaud, E Hachulla, R Jouenne, B Combe, ... Arthritis & Rheumatism 62 (8), 2458-2466, 2010 | 465 | 2010 |
| Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers O Lambotte, G Ferrari, C Moog, NL Yates, HX Liao, RJ Parks, CB Hicks, ... Aids 23 (8), 897-906, 2009 | 424 | 2009 |
| Reactive hemophagocytic syndrome in adults: a retrospective analysis of 162 patients S Rivière, L Galicier, P Coppo, C Marzac, C Aumont, O Lambotte, L Fardet The American journal of medicine 127 (11), 1118-1125, 2014 | 380 | 2014 |
| Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer A Simonaggio, JM Michot, AL Voisin, J Le Pavec, M Collins, A Lallart, ... JAMA oncology 5 (9), 1310-1317, 2019 | 346 | 2019 |
| Autoimmune and inflammatory manifestations occur frequently in patients with primary immunodeficiencies A Fischer, J Provot, JP Jais, A Alcais, N Mahlaoui, D Adoue, N Aladjidi, ... Journal of Allergy and Clinical Immunology 140 (5), 1388-1393. e8, 2017 | 328 | 2017 |
| The enteropathy associated with common variable immunodeficiency: the delineated frontiers with celiac disease G Malamut, V Verkarre, F Suarez, JF Viallard, AS Lascaux, J Cosnes, ... Official journal of the American College of Gastroenterology| ACG 105 (10 …, 2010 | 321 | 2010 |
| Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial PL Tharaux, G Pialoux, A Pavot, X Mariette, O Hermine, M Resche-Rigon, ... The Lancet Respiratory Medicine 9 (3), 295-304, 2021 | 298 | 2021 |
| Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection S Reuse, M Calao, K Kabeya, A Guiguen, JS Gatot, V Quivy, C Vanhulle, ... PloS one 4 (6), e6093, 2009 | 295 | 2009 |
